|
|
Vaccine Detail
|
Recombinant Vaccinia-NY-ESO-1 Vaccine |
| Vaccine Information |
- Vaccine Name: Recombinant Vaccinia-NY-ESO-1 Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007041
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Antigen: NY-ESO-1
- CTAG1B
gene engineering:
- Description: This is for various Cancer (NCT00112957). A cancer vaccine consisting of a recombinant vaccinia viral vector encoding an immunogenic peptide derived from the cancer-testis antigen NY-ESO-1, an antigen found in normal testis and various tumors, including bladder, breast, hepatocellular, melanoma, and prostate cancers. Vaccination with recombinant vaccinia NY-ESO-1 peptide vaccine may stimulate the host immune system to mount a humoral and cytotoxic T lymphocyte (CTL) response against tumor cells expressing NY-ESO-1 antigen, resulting in tumor cell lysis (NCI05) (NCIT_C48419).
|
| Host Response |
|
|
| References |
Lattanzi et al., 2018: Lattanzi M, Han J, Moran U, Utter K, Tchack J, Sabado RL, Berman R, Shapiro R, Huang HH, Osman I, Bhardwaj N, Pavlick AC. Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis. Journal for immunotherapy of cancer. 2018; 6(1); 38. [PubMed: 29773080].
NCIT_C48419: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48419]
NCT00112957: [https://clinicaltrials.gov/show/NCT00112957/]
|
|
